Precipio Q1 revenue rises on higher pathology sales

Precipio

14/05/2026 22:31

Overview

US specialty cancer diagnostics firm's Q1 revenue rose yr/yr, driven by higher pathology sales

Adjusted EBITDA for Q1 was negative, reflecting increased costs and delayed product shipments

Company reported positive cash flow from operations, but overall cash burn due to bonus payments

Outlook

Company expects delayed product revenue to be recognized in Q2 due to shipment timing

Company says underlying business fundamentals, especially the product pipeline, continue to grow

Result Drivers

PRODUCT SHIPMENT DELAY - Decline in product revenue and gross profit was largely due to a delayed shipment to a major customer, shifting revenue to Q2

CMS REIMBURSEMENT CUTS - Pathology gross profit decreased due to CMS cuts

HIGHER OPERATING COSTS - Increased costs from hiring a product business development team impacted results

Company press release: ID:nGNX3sg9xV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$6.71 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)